Vitroscope raises $7M in a seed round to enhance drug discovery using living human tissue. The funding was co-led by Cerberus Ventures and YZR Capital.
Vitroscope, a biotech company, has successfully raised $7 million, including a $5 million seed round. The funding, which also comprises $2 million in non-dilutive support, will enable the company to advance its perfusion platforms for drug discovery. Leading the investment were Cerberus Ventures and YZR Capital, with participation from several other investors. This funding will help Vitroscope expand its technology into more laboratories.
Who to call at Vitroscope, and when
A new round usually means Vitroscope is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Vitroscope raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Vitroscope, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vitroscope. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Vitroscope
About
Vitroscope is a biotech company that develops perfusion platforms to study immune activity, treatment responses, and disease mechanisms in real time. Their platforms enable researchers to observe living tissue over extended periods, generating valuable data for drug discovery. Vitroscope's technology addresses limitations in traditional experimental models by maintaining optimal conditions for tissue viability and data collection. The company aims to revolutionize drug discovery by providing new data-driven insights into biological responses.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vitroscope raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
